

May 23, 2018

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Reconciliation of Equity

Ref: Email and NSE Letter NSE/LIST/FR/5931 dated May 22, 2018 for submission of Standalone Reconciliation of Equity


Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

With reference to financial results submitted by the Company on May 21, 2018 and in further reference to your email and letter as stated above, please find enclosed the Standalone Reconciliation of Equity.

We request you to kindly take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

The reconciliation of Total Equity (Shareholder's Funds) reported in accordance with Indian GAAP and Total Equity reported in accordance with Ind AS is given below:

Particulars	Rs. in lakhs
	As at 31 March, 2017
Equity under Previous GAAP	18,045.66
Adjustments:	
Provision for expected credit loss	(59.81)
Reversal of rent equalisation reserve	107.11
Employee stock compensation plan	299.73
Deferred tax asset	4,021.71
Others	(127.59)
Total Equity as per Ind AS	22,286.81

For AstraZeneca Pharma India Limited


Gagan Singh Bedi
Managing Director

Vandana